BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Biotech Beach

  Skye Bioscience to Present at Upcoming Investment Conferences - April 23, 2024

  Skye Bioscience, Inc. announced that Chief Executive Officer & Chair Punit Dhillon and other members of Skye’s executive team will present the company and its programs in obesity and glaucoma at the following investment conferences.

  April 23, 2024

   · 

  3 min read
• Policy

  Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program

  Tiziana Life Sciences, Ltd. announced that the U.S. Food and Drug Administration has allowed its intranasal foralumab non-active Secondary Progressive Multiple Sclerosis Expanded Access Program to expand from 10 patients to a total of 30 patients.

  April 23, 2024

   · 

  5 min read
• Drug Development

  AAVantgarde presents positive preclinical data in large animal models from its Stargardt disease program in an oral presentation at the ASGCT 2024 annual meeting

  AAVantgarde Bio announces the publication of an abstract accepted as an oral presentation submitted to The American Society of Gene & Cell Therapy 27th Annual Meeting, to be held May 7-11 in Baltimore.

  April 23, 2024

   · 

  2 min read
• Genetown

  Red Arrow Therapeutics Inc. closes $4.5M Seed Extension round

  Red Arrow Therapeutics Inc. closed a $4.5M Seed Extension round, raising from four, top-tier institutional investors in Japan.

  April 23, 2024

   · 

  1 min read
• Pharm Country

  Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

  Century Therapeutics today announced that members of the management team will participate in a virtual fireside chat and panel at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit.

  April 23, 2024

   · 

  1 min read
• Policy

  Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID

  Revive Therapeutics Ltd. announced that the U.S. Food & Drug Administration has granted the Company’s Type C meeting request for the evaluation of a proposed clinical study of Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long COVID.

  April 23, 2024

   · 

  5 min read
• Drug Development

  Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder

  Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced positive topline data for its Phase 2 SAVITRI™ study. This randomized, double-blind, placebo-controlled dose-finding study assessed the efficacy and safety of NBI-1065845 in adult subjects with major depressive disorder (MDD).

  April 23, 2024

   · 

  7 min read